Innovative InsurTech Firm Aixuan Technology Secures Tens of Millions in Series A++ Funding Led by Zhuhai Rongqian Fund

VCBeat has learned that Beijing Aixuan Information Technology Co., Ltd. (“Aixuan Tech”), an innovative insurance product provider, recently announced the completion of its A++ round of financing, led by Zhuhai Rongqian, with participation from Shenghui Capital and prominent industrial investors.

This round of financing will be used to accelerate the team building at AIXUAN Technology, increase investment in the research and development of innovative insurance products, and advance the commercial implementation of core product services such as actuarial risk control and intelligent underwriting. By doing so, the company aims to continuously meet the needs of enterprises and individuals, seize excellent opportunities in the life and health insurance markets, build a more competitive super-platform within the “pharmaceuticals, healthcare, and insurance” ecosystem, and consistently support the industry’s high-quality, high-value development.

Founded in 2017, Aixuan Technology is an insurtech company co-established by senior insurance industry executives and a team of actuarial experts. Since its inception, Aixuan Technology has been committed to building a supermarket within the “pharmaceuticals, healthcare, insurance, and wellness” ecosystem. It has deeply cultivated emerging commercial sectors such as interactive insurance policies tailored for the elderly, individuals with pre-existing conditions, and the general population. Leveraging its dual advantages of proprietary technological barriers and market recognition, the company has partnered with multiple insurers to launch exclusive, customized blockbuster products, continuously strengthening its presence in the realm of highly customized commercial insurance. Furthermore, Aixuan Technology provides insurance product pricing and real-time risk assessment services for both high-to-moderate and standard-risk populations. Building on these capabilities, it integrates data, expert expertise, and algorithm-driven solutions to create a closed-loop system for comprehensive health management.

To date, Aishuan Technology has established in-depth collaborations with numerous insurance institutions and channel platforms, marking a significant step toward the deep integration of health, medical care, and lifestyle services with insurance. This approach not only facilitates the expansion of the insured population but also ensures reasonable profitability and risk management, serving as a key indicator of its strategic positioning in the future blue-ocean market for non-standard risk individuals.

Meanwhile, iSelection Technology maintains long-term research collaborations with renowned academic institutions both domestically and internationally, primarily focusing on the application of big data, actuarial science, and artificial intelligence in the insurance and healthcare sectors. The company strives to identify, predict, and manage disease and mortality risks more rapidly, accurately, and scientifically.

In collaboration with reinsurers, insurance companies, and health service providers, Aixuan Technology has launched a comprehensive solution encompassing insurance product design and pricing, risk control, health management, and sales promotion. First, it meets the multifaceted needs of both insurers and consumers through innovation in coverage responsibilities and services. Second, it establishes a foundation for product pricing, underwriting risk control, and reinsurance arrangements. By strategically integrating the “pharmaceuticals, healthcare, insurance, and wellness” super-ecosystem, it fosters an innovative matrix of ecosystem-based insurance products. Leveraging accumulated multi-source data, intelligent actuarial models, and smart underwriting systems, it builds competitive barriers in product design and underwriting risk control, while assisting insurers in strictly maintaining product quality across multiple channels. Third, through its publicity and training teams, it collaborates with insurers to formulate marketing strategies prior to product launch and empowers sales personnel post-launch, thereby helping insurers achieve their sales targets.

In its pursuit of product innovation and operations, iSelect Technology has maintained a steady yet rapid pace, successively launching best-selling products such as Ping An Property & Casualty’s “E-Sheng Ping An” Filial Piety Insurance (Premium Edition), Dajia Property & Casualty’s Fu Lu Shou Medical Insurance for Middle-Aged and Elderly Individuals, and China Life Property & Casualty’s Tang Anxin.

Yu Yongping, Partner at Junhao Capital’s Healthcare Fund, stated: “The insurance industry is characterized by its large scale and high growth potential, with payers wielding greater influence in medical innovation. However, severe product homogenization currently prevails, making innovation an urgent priority for the sector. Aishuan Technology has been deeply entrenched in the insurance industry for many years, continuously launching innovative insurance products leveraging its foundational data and professional expertise. By extending its offerings outward from these core products, it has become a vital link in the insurance value chain. We are highly optimistic about the company’s prospects and hope that Aishuan will continue to innovate, further expanding into the blue-ocean market for non-standard risks. Meanwhile, we will remain committed to supporting Aishuan’s development.”

Zhuhai Rongqian Fund was jointly established in 2019 by Junhao Capital and Huarong Rongde, focusing on investments in technology-driven startups in the healthcare industry. To date, it has invested in 17 projects, including Zhidao Biology, Rou Dian Yun Ke, and Nuokangda. Junhao Capital, formerly known as ICBC International Rongtong Capital, is a leading alternative asset management platform in China with superior performance and assets under management (AUM) exceeding RMB 65 billion. The healthcare sector is one of Junhao Capital’s key focus areas, with investments in outstanding companies such as Jialin Pharmaceutical, Ribobio, and Yaoxin Biotech.

Huarong Rongde was established in 2006 as a Sino-foreign joint venture asset management company jointly founded by China Huarong and Deutsche Bank. In early 2016, the company recruited industry talent to build a multidisciplinary healthcare investment team with deep sector research capabilities and extensive industrial experience. Leveraging the asset management platform, the team pioneered innovations and developed its healthcare investment business from the ground up, making it a key pillar of the company’s investment operations. It has completed equity investments in more than 40 outstanding healthcare companies, with cumulative investments exceeding RMB 4 billion. Notable portfolio companies include Mabwell Therapeutics, HaiChuang Pharmaceuticals, Bloomage Biotechnology, United Imaging Healthcare, KangLe WeiShi, Changfeng Pharmaceutical, and Shengsi Biologics, among others, with several having successfully gone public.